Thursday, September 10, 2026
ExploreSearch
Via News
Via News Knowledge File

BioNTech SE

organization80% conf.·synced Aug 13, 2026

Biotechnology company involved in patent litigation with Moderna

30
sourced metrics
482
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Clinical Programs
17programs
source
Parameter Count
6asco_2026_presentations
May 22, 2026source
Shareholder Attendance
92percent
May 15, 2026source
Supervisory Board Size
8members
May 15, 2026source
Combination Therapy Trials
5trials
Mar 24, 2026source
Ongoing Clinical Trials
16trials
Mar 24, 2026source
Ongoing Novel Novel Combination Trials
5trials
Mar 24, 2026source
Active Lung Cancer Trials
16trials
Mar 24, 2026source
Phase 3 Trials
4trials
Mar 24, 2026source
Ongoing Phase3 Trials
4trials
Mar 24, 2026source
Company Age
18years
Mar 10, 2026source
Novel Novel Combination Trials
10trials
Jan 12, 2026source
Phase 2 3 Trials Count
25trials
Jan 12, 2026source
Combination Therapy Trials Count
10trials
Jan 12, 2026source
Phase 3 Trials Count
15trials
Jan 12, 2026source
Phase 2 3 Trials
25trials
Jan 12, 2026source
Cash
17.2USD
Dec 31, 2025source
Revenue
2.6-2.8billion_EUR
Nov 30, 2025⚠ sources conflictsource

Stated objectives

2025 R&D expenses target

source
target: EUR 2.0B-EUR 2.2B by 2025-12-31 00:00:00stated

2025 SG&A expenses target

source
target: $550M-$650M by 2025-12-31 00:00:00stated

2025 CapEx for operations target

source
target: $200M-$250M by 2025-12-31 00:00:00stated

Transition to fully integrated commercial oncology company

source
by 2025-12-31 00:00:00stated

Achieve FY 2025 revenue between €2,600M and €2,800M

source
target: 2600-2800 by 2025-12-31 00:00:00stated

Reduce R&D costs to €2,000-2,200M for FY 2025

source
target: 2000-2200 by 2025-12-31 00:00:00stated

Reduce SG&A costs to €550-650M for FY 2025

source
target: 550-650 by 2025-12-31 00:00:00stated

Reduce CapEx to €200-250M for FY 2025

source
target: 200-250 by 2025-12-31 00:00:00stated

File BLA for Trastuzumab Pamirtecan in 2026 pending FDA feedback

source
by 2026-12-31 00:00:00stated

Initiate ROSETTA Breast-01 Phase 3 trial for TNBC by end of 2025

source
by 2025-12-31 00:00:00stated

Relationship graph · 482 connections

Developed by
103
Partnered with
85
Employs
52
Partners with
35
Invested in
34
founded
29
headquartered in
23
Customer of
21
headquartered in
Mainz, Germany
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Boom Meets Valuation Jitters: Funding Surges While Bellwether Stocks Wobble
A dense wave of AI-sector funding (Socure, Stability AI, Emerald AI, Generalist AI, Gatik, Regent Craft and others closing rounds on the same day) and strong enterprise-automation earnings (UiPath raising full-year guidance) point to continued heavy capital deployment into AI infrastructure, fintech-adjacent AI, and agentic automation. Yet Palantir's stock fell even after winning the Army's high-profile TITAN contract, and commentary (e.g., the Alphabet bull case citing AI capex and regulatory risk) signals growing investor unease about whether current AI valuations and spending levels are sustainable.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,278 source documents archived
Query this data → isubstrate.com